CEO Paul John Buys 60,200 Shares as DiaMedica Signals Confidence in Upcoming Clinical Milestones
DiaMedica CEO Paul John buys 60k shares—signal of confidence in preeclampsia data & future trial milestones.
3 minutes to read
DIAMEDICA THERAPEUTICS INC
DIAMEDICA THERAPEUTICS INSIDER BUY‑BACK: Executives Dump Massive Option Grants Amid Volatile Market, Signaling High‑Risk Confidence in Future Pipeline.
Insider buying at DIAMEDICA THERAPEUTICS shows executive confidence in its clinical pipeline and future growth, but investors must weigh the potential volatility and earnings risk.
3 minutes to read